Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT Study of Sipagladenant (KW-6356) in Japanese Healthy Adults
NCT04342273Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sipagladenant in Parkinson's disease (PD) (4 arms), sponsored by Kyowa Kirin. Primary endpoint: Change from baseline in QTc interval [QTcF]. Started Mar 2020; status: completed.
02
Drugs
sipagladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04342273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04342273.